Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis

This publication has 16 references indexed in Scilit:

• A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
  Haematologica, 2012
• Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
  Blood, 2011
• Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure
  Transplantation, 2010
• Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy
  The Journal of Heart and Lung Transplantation, 2008
• The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
  Blood, 2006
• Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis
  Blood, 2006
• Critical Influence of Natural Regulatory CD25+ T Cells on the Fate of Allografts in the Absence of Immunosuppression
  Transplantation, 2005
• Regulatory T Cells in Transplantation: Natural or Induced?
  Transplantation, 2005
• Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
  Blood, 2004
• Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs
  The Journal of Pharmacology and Experimental Therapeutics, 2003